Beyond PACIFIC: Real-World Outcomes of Adjuvant Durvalumab According to Treatment Received and PD-L1 Expression

Beyond PACIFIC: Real-World Outcomes of Adjuvant Durvalumab According to Treatment Received and PD-L1 Expression

Adjuvant durvalumab after chemoradiotherapy (CRT) is the standard of care for unresectable stage III non-small cell lung cancer (NSCLC). A post hoc exploratory analysis of PACIFIC revealed no OS benefit in the PD-L1 < 1% subgroup. This retrospective analysis assesses the real-world impact of durv...

Full description

Bibliographic Details
Main Authors: Marie-Hélène Denault, Jamie Feng, Shelley Kuang, Aria Shokoohi, Bonnie Leung, Mitchell Liu, Eric Berthelet, Janessa Laskin, Sophie Sun, Tina Zhang, Cheryl Ho, Barbara Melosky
Format: Article
Language:English
Published: MDPI AG 2023-08-01
Series:Current Oncology
Subjects:
locally advanced non-small cell lung cancer
durvalumab
adjuvant
immune checkpoint inhibitors
PD-L1
Online Access:https://www.mdpi.com/1718-7729/30/8/543

Similar Items

Similar Items